Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Provigil Reformulation Will Be Filed With FDA By Year-End

Executive Summary

Cephalon's $100 mil. in new financing from a preferred stock offering finalized on Aug. 13 will help tide the company over while it develops new indications for its lead drug, wakefulness agent Provigil.

You may also be interested in...



Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino

About 40% of scripts for Cephalon's narcolepsy therapy Provigil (modafinil) are being written for off-label indications, Cephalon CEO Frank Baldino said at a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.

Cephalon's Provigil Produces Eye-Opening 40% Off-label Use - CEO Baldino

About 40% of scripts for Cephalon's narcolepsy therapy Provigil (modafinil) are being written for off-label indications, Cephalon CEO Frank Baldino said at a Burns McClellan/Petkevich & Partners analyst meeting in London Oct. 6.

Abbott Gabitril

Cephalon will co-promote the anti-epileptic Gabitril (tiagabine) beginning in September. The company will increase its neurology sales force, which markets the narcolepsy therapy Provigil (modafinil), from 45 to 85 for the launch. Abbott also has an option to co-promote Provigil if Cephalon seeks a U.S. marketing partner

UsernamePublicRestriction

Register

PS034666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel